Repligen Corporation to Present at Upcoming Investor Conferences
Repligen to Report Third Quarter 2024 Financial Results
Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Q3 Release [Yahoo! Finance]
Peptide Therapeutics Industry Report 2024, Featuring Profiles of 30+ Leading Players Including PeptiDream, PolyPeptide, Repligen, X-GEN Pharmaceuticals, Zydus Cadila and More [Yahoo! Finance]
Repligen Co. (NASDAQ: RGEN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $205.00 price target on the stock.